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Background: Based on resistance of currently used anti-malarials, a new anti-malarial drug target against Plasmodium
falciparum is urgently needed. Damaged DNA cannot be transcribed without prior DNA repair; therefore, uracil-DNA
glycosylase, playing an important role in base excision repair, may act as a candidate for a new anti-malarial drug
target.
Methods: Initially, the native PfUDG from parasite crude extract was partially purified using two columns, and the
glycosylase activity was monitored. The existence of malarial UDG activity prompted the recombinant expression
of PfUDG for further characterization. The PfUDG from chloroquine and pyrimethamine resistant P. falciparum strain
K1 was amplified, cloned into the expression vector, and expressed in Escherichia coli. The recombinant PfUDG was
analysed by SDS-PAGE and identified by LC-MS/MS. The three dimensional structure was modelled. Biochemical
properties were characterized. Inhibitory effects of 12 uracil-derivatives on PfUDG activity were investigated. Inhibition
of parasite growth was determined in vitro using SYBR Green I and compared with results from human cytotoxicity
tests.
Results: The native PfUDG was partially purified with a specific activity of 1,811.7 units/mg (113.2 fold purification). After
cloning of 966-bp PCR product, the 40-kDa hexa-histidine tagged PfUDG was expressed and identified. The amino acid
sequence of PfUDG showed only 24.8% similarity compared with the human enzyme. The biochemical characteristics
of PfUDGs were quite similar. They were inhibited by uracil glycosylase inhibitor protein as found in other organisms.
Interestingly, recombinant PfUDG was inhibited by two uracil-derived compounds; 1-methoxyethyl-6-(p-n-octylanilino)
uracil (IC50 of 16.75 μM) and 6-(phenylhydrazino)uracil (IC50 of 77.5 μM). Both compounds also inhibited parasite growth
with IC50s of 15.6 and 12.8 μM, respectively. Moreover, 1-methoxyethyl-6-(p-n-octylanilino)uracil was not toxic to HepG2
cells, with IC50 of > 160 μM while 6-(phenylhydrazino)uracil exhibited cytoxicity, with IC50 of 27.5 μM.
Conclusions: The recombinant PfUDG was expressed, characterized and compared to partially purified native PfUDG.
Their characteristics were not significantly different. PfUDG differs from human enzyme in its size and predicted
amino acid sequence. Two uracil derivatives inhibited PfUDG and parasite growth; however, only one non-cytotoxic
compound was found. Therefore, this selective compound can act as a lead compound for anti-malarial development
in the future.
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Malaria is an important infectious disease caused by Plas-
modium parasites, for which Plasmodium falciparum is
found prevalently and causes virulent symptoms. The dis-
ease is endemic in more than 100 countries and causes
approximately 655,000 deaths worldwide [1]. The most
serious problem for malaria treatment is the development
of resistance of the parasites to existing anti-malarial drugs
including the most effective drug, artemisinin, which has
been used as first-line treatment in many countries [1-6].
The discovery of new drug targets would be an effect-
ive strategy for combating multidrug resistant malaria.
Many enzymes involved in biosynthesis and metabolic
processes such as membrane biosynthesis [7,8], mem-
brane transport [9], proteases [10-12], redox system
[13,14] and mitochondrial system [15,16] have been in-
vestigated for their potential as anti-malarial drug tar-
gets. However, very little is known about malarial DNA
repair system and its significance.
DNA repair is essential for parasite existence to pre-
vent gene mutations by both spontaneous mutation dur-
ing DNA replication of cell division and drug-induced
mutation. Base excision repair (BER), for example, plays
a major role in removing a damaged base followed by re-
placement of the correct base into DNA [17,18]. There-
fore, enzymes involved in BER should be explored for
their roles as new drug targets against malaria. DNA
glycosylases are the first enzymes in the BER pathway,
and recognizing specific damaged bases, they act as the
key enzymes to drive the BER process. Uracil-DNA gly-
cosylase (UDG) is a specific DNA glycosylase for uracil
cleavage. This base is introduced by cytosine deamin-
ation, which occurs as frequently as 100–500 times/cell/
day [19]; therefore, this enzyme plays very important
role in preventing G:C to A:T transition mutation.
UDGs of many organisms have been characterized for
their biochemical properties, for example the bacterial
enzymes (Escherichia coli [20,21]), viral enzymes (pox-
virus [22], HSV-1 [23]), parasite enzyme (Trypanosoma
cruzi [24]), and human enzyme [25-27]. Moreover, UDG
inhibitors should be considered for targeting to PfUDG.
Two types of UDG inhibitors, uracil glycosylase inhibitor
(UGI) protein and uracil-derived compounds have been
studied. The UGI is a well-known UDG inhibitor isolated
from bacteriophage PBS 1 and 2 specific to Bacillus
subtilis. This protein inhibited UDG of several organisms
[28-31]. The uracil-derived compounds, 6-(p-alkylanilino)
uracils, were reported to inhibit HSV-1 UDG by acting as
uracil analogs to bind competitively to the catalytic amino
acid residues in the active site motif of UDG [23,32,33].
Because UDG is essential for conservation of genome
integrity and normal function of encoding proteins of
organisms including the malaria parasite, P. falciparum,
therefore in this study P. falciparum UDG (PfUDG) wassuccessfully cloned and expressed, and the native en-
zyme was also partially purified. PfUDG activity was
determined, and properties of both recombinant and
native enzymes were characterized. Inhibitory effects of
12 uracil-derived compounds on enzyme and parasite
growth were investigated, and their cytotoxicities were
determined. Results obtained were promising for further
design of a new anti-malarial drug against P. falciparum,
especially against drug resistant strains worldwide.
Methods
Preparation of partially purified native PfUDG
Plasmodium falciparum K1 strain, a chloroquine and
pyrimethamine resistant strain from Thailand [34], was
cultured in RPMI 1640 (Invitrogen, CA, USA) supple-
mented with 10% human serum and human red blood
cells (RBC) at 37°C in an atmosphere containing 5%
CO2. The RBC-packed parasites with 20-25% parasit-
aemia were harvested by centrifugation at 664xg at 25°C
for 7 min. The parasite pellet was prepared by incuba-
tion of RBC-packed parasites with an equal volume of
phosphate buffered saline (PBS), pH 7.6, containing
0.15% (w/v) saponin at 37°C for 20 min. The suspension
was washed with PBS by centrifugation at 664xg at 25°C
for 10 min until the supernatant was clear, and the para-
site pellet was kept at −80°C until used.
Approximately 2 ml of parasite pellet was resuspended
in three volumes of extraction buffer containing 50 mM
Tris–HCl pH 7.6, 1 mM EDTA, 2 mM DTT, 1 mM
PMSF, and 0.01% NP-40. Parasite cells in suspension
were disrupted by Dounce homogenization, and nucleo-
protein was extracted by 0.5 M KCl with stirring on ice
for 30 min. The suspension was centrifuged at 17,600xg
for 40 min at 4°C, and the supernatant was dialysed at
4°C overnight against buffer A containing 25 mM Tris–
HCl pH 9.0, 1 mM EDTA, 2 mM DTT, 1 mM PMSF,
0.01% NP-40, 5% sucrose, and 20% glycerol.
Partial purification of native PfUDG
The dialysed crude extract was loaded onto a 1 ml
HiTrap™Capto™Q (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden) column, and purified by using FPLC®Sys-
tem (Pharmacia Biotech AB, Uppsala, Sweden) at a flow
rate of 1 ml/min at 4°C. The unbound fractions were col-
lected, and the column was washed with 10 column vol-
umes (CV) of buffer A. The bound proteins were then
eluted with 15 CV of 0-100% KCl linear gradient in buffer
A. Both unbound and bound fractions were assayed for
UDG enzymatic activity. The fractions containing PfUDG
were pooled and dialysed at 4°C overnight against buffer B
containing 50 mM HEPES pH 8.5, 1 mM EDTA, 2 mM
DTT, 1 mM PMSF, 0.01% NP-40, 5% sucrose, and 20% gly-
cerol. The dialysed fraction was then loaded onto a 1 ml
Hitrap™ Heparin HP (GE Healthcare Bio-Sciences AB)
Table 1 Composition of single stranded oligonucleotides
used in UDG activity assay
Oligonucleotide Sequence: 5'-3'
oligo-U GAC ACG TCA GAT AGC ATG ACA
UCG AGC TGC AGG ACT GAT CT
oligo-A AGA TCA GTC CTG CAG CTC GAT
GTC ATG CTA TCT GAC GTG TC
oligo-T AGA TCA GTC CTG CAG CTC GTT
GTC ATG CTA TCT GAC GTG TC
oligo-G AGA TCA GTC CTG CAG CTC GGT
GTC ATG CTA TCT GAC GTG TC
oligo-C AGA TCA GTC CTG CAG CTC GCT
GTC ATG CTA TCT GAC GTG TC
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proteins were collected and the column was washed with
10 CV of buffer B. The column was then eluted with 15
CV of 0-100% KCl linear gradient in buffer B. Fractions
containing PfUDG were pooled and termed native PfUDG.
Construction of PfUDG expression vector
The genomic DNA P. falciparum K1 strain was the
source of genomic DNA used as a template in PCR to
generate full-length PfUDG. The full-length gene was
amplified by using specific primers: PfUDG-forward 5'-
CACCATGAATAATCCAACAATT-3' and PfUDG-re-
verse 5'-TTGGGGTAGCTCCCATTTG-3'. The amplifi-
cation was done by initial denaturing at 95°C for 5 min
followed by 35 cycles of reaction with denaturing at
95°C for 1 min, annealing at 58°C for 1 min, extension
at 72.5°C for 1 min after each cycle, and final extension
at 72.5°C for 3 min. The PCR product was analysed by
1% agarose gel electrophoresis. The amplified full-length
PfUDG was cloned into pET101/D-TOPO expression
vector using Champion™pET Directional TOPO Expres-
sion System (Invitrogen) at a 1.5 to 1 molar ratio of the
gene fragment and the vector. The constructed vector
was named pET101D-PfUDG, and the sequence was
analysed for base sequence correction by BioDesign,
Pathumthani, Thailand.
Expression and purification of recombinant PfUDG
The pET101D-PfUDG vector was transformed into E.
coli Rosetta (DE3) pLysS and grown on LB agar contain-
ing 100 μg/ml ampicillin and 20 μg/ml chloramphenicol
at 37°C overnight. A single colony was picked and grown
in 10 ml of LB broth containing 100 μg/ml ampicillin
and 20 μg/ml chloramphenicol at 37°C overnight. The
overnight culture was inoculated into 1 L of LB broth
containing 0.5 M sorbitol, 100 μg/ml ampicillin and
20 μg/ml chloramphenicol, and incubated at 37°C with
shaking at 180 rpm until the optical density at 600 nm
reached 0.4. PfUDG expression was induced with
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG),
and bacteria were further incubated at 37°C with shaking
for 1 hr. The bacteria were then harvested by centrifuga-
tion at 1,600xg for 20 min, washed with buffer, pH 8.0,
containing 50 mM NaH2PO4 and 300 mM NaCl, and
centrifuged at 1,600xg for 20 min. The bacterial pellet
was resuspended in 200 ml of cold lysis buffer, pH 8.0,
containing 50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, and 1 mM PMSF, and disrupted by a XL 2020
Sonicator® Ultrasonic Processor XL (Heat System Inc.,
NY, USA). The total soluble protein was fractionated
by centrifugation at 17,600xg at 4°C for 20 min. The
expressed protein was analysed by SDS-PAGE.
The total soluble protein was loaded onto a Ni-NTA
agarose affinity column (QIAGEN, Hilden, Germany)pre-equilibrated with 10 CV of cold lysis buffer with
gravity flow. The column was washed continuously with
12 CV of cold washing buffer, pH 8.0, containing 50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, and 1 mM
PMSF, and protein was then eluted with 8 CV of cold elut-
ing buffer, pH 8.0, containing 50 mM NaH2PO4, 300 mM
NaCl, 250 mM imidazole, and 1 mM PMSF. The flow-
through, washed and eluted fractions were collected, and
protein concentration was measured by Bradford’s assay
(Bio-Rad Laboratories, CA, USA). The protein purity was
analysed using SDS-PAGE.
Identification of PfUDG by LC-MS/MS and 3D modelling
of PfUDG
The expected protein bands were cut from the gel and
digested with trypsin to get peptide fragments. The pat-
tern of peptide fragments and amino acid sequences were
analysed using LC-MS/MS and identified by MASCOT
software [35]. The 3D structure of PfUDG was built from
predicted amino acid sequences of the full-length PfUDG
protein compared to human UDG PDB code 3FCF using
SWISS MODEL modelling server in http://swissmodel.
expasy.org [36-38]. Geometry optimization was performed
in a water box plus ions, and geometry of conformers was
validated by PROCHECK [39].
Preparation of UDG activity assay substrates
The 41-mer uracil-containing single stranded oligonucleo-
tide (oligo-U) and various 41-mer uracil-containing double
stranded oligonucleotides, A:U, T:U, C:U, and G:U, were
used as substrates in PfUDG activity assay. The sequences
of oligonucleotides are shown in Table 1.
The oligo-U was 5' end radiolabelled with γ-32P ATP.
A 100 μl reaction volume containing 70 mM Tris–HCl
pH 7.6, 10 mM MgCl2, 5 mM DTT, 1 unit T4 poly-
nucleotide kinase (New England BioLabs, MA, USA),
20 pmol γ-32P ATP (Perkin Elmer, MA, USA) and 200
pmol oligo-U, was incubated at 37°C for 30 min. The
reaction was terminated by heating the mixture at
65°C for 20 min. The double stranded substrates were
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stranded oligo-U to single stranded oligo-A, −T, −C,
and -G in 50 μl reaction volumes containing 70 mM
Tris–HCl pH 7.6, 10 mM MgCl2, and 5 mM DTT. The
reactions were initially heated at 95°C for 5 min and
allowed to cool to room temperature for 3 hr.
Enzymatic assay and biochemical characterization
The UDG activity assay (20 μl) consisted of standard re-
action buffer containing 20 mM Tris–HCl pH 8.0,
1 mM DTT, 1 mM EDTA, 50 mM NaCl, 100 μg/ml
BSA, 10 pmol 32P-labelled oligo-U, and 20 ng of PfUDG
at 37°C for 20 min. The glycosylase activity was stopped
by heating at 100°C for 1 min, the resulting apurinic/
apyrimidinic site (AP site) was incised by hot alkaline
treatment with 0.1 M NaOH (final concentration) at
95°C for 10 min, and the reaction was neutralized with
0.1 M HCl (final concentration). The AP lyase activity
assay of PfUDG was examined under the same condition
as UDG activity assay except without hot alkaline treat-
ment. Reaction products were analysed on 8 M urea-
16% denaturing PAGE and exposed to X-ray film for
autoradiography for visualization. The radioactive inten-
sity of sliced substrate and product bands from the gel
were measured in a 1450 MicroBeta® Trilux Liquid Scin-
tillation Counter (Perkin Elmer) as counts per minute
(cpm). The amounts of substrate and product (pmol)
were determined from radioactive intensity. One unit of
activity is defined as the amount of PfUDG required for
releasing 1 pmol of uracil in 1 min at 37°C in standard
reaction buffer (20 mM Tris–HCl pH 8.0, 50 mM NaCl,
1 mM EDTA, 1 mM DTT, and 100 μg/ml BSA) with
32P-labelled single stranded oligo-U substrate.
Biochemical properties of native and recombinant
PfUDGs were characterized based on UDG activity under
different reaction conditions including temperature, pH,
salt concentration, cofactors, and substrate preference.
The effects of various temperatures ranging from 4-65°C
on enzyme activity were tested. PfUDG was also tested at
different buffer conditions: phosphate-citrate buffer for
pH 4–7, 20 mM Tris–HCl for pH 7.5-8.5, and glycine-
NaOH buffer for pH 9–10.5. Effects of NaCl on PfUDG
were investigated by using various NaCl concentrations
(5–500 mM). In addition, various concentrations of diva-
lent cation cofactors including MgCl2, MnCl2, and CaCl2
at 1, 10, 50, and 100 mM were tested. Relative activity of
PfUDG was determined as above by radioactive intensity
(cpm) of product divided by total cpm of substrate and
product.
To determine steady state kinetic parameters (Km, Vmax)
for different substrates of the recombinant PfUDG, con-
centrations of 32P-labelled substrates were varied from
0.01 to 3.5 μM. The reaction was initiated by adding 2.5
nM PfUDG (2 ng) to the reaction mixture and incubatedat 37°C for 10 min. The kinetic parameters, Km and kcat,
were calculated based on the Michaelis-Menten equation
using non-linear least square algorithm in SigmaPlot 12.0.
Inhibitory effects of UDG inhibitors on PfUDG
Two types of UDG inhibitors, UGI protein and synthetic
uracil-derived compounds, were tested for their inhibi-
tory effects on PfUDG. UGI protein of B. subtilis
bacteriophage PBS1 (New England BioLabs) was used
against native and recombinant PfUDG with 10 pmol
32P-labelled single stranded oligo-U in the standard
reaction buffer at 37°C for 20 min. The synthetic uracil-
derived compounds were also used at various concentra-
tions (5–640 μM) with 20 ng of recombinant PfUDG
and 10 pmol 32P-labelled single stranded oligo-U in the
standard reaction buffer at 37°C for 20 min. The same
0.4% (v/v final concentration) of DMSO was used as
solvent control to determine its effects on enzyme activ-
ity. The dose–response curves of relative activities of
PfUDG and various compound concentrations were gen-
erated, and half-maximal inhibitory concentration (IC50),
the concentration of compound to inhibit enzyme activ-
ity by 50%, was obtained using SigmaPlot 12.0.
Inhibition of parasite growth using an in vitro assay
The synchronized ring stage of P. falciparum K1 strain
was prepared from mixed stage parasite culture by 5%
D-sorbitol treatment. The ring stage parasite was then
mixed with culture medium containing RPMI 1640 sup-
plemented with 10% human serum. Various concentra-
tions of each uracil-derived compound were tested at
2-fold serial dilutions in triplicate. Their inhibitory
effects on parasite growth were determined by SYBR
Green I based assay [40]. The fluorescent intensity
was measured by Varioskan Flash Multimode Reader
(Thermo Scientific, Vantaa, Finland) with excitation and
emission wavelengths of 485 and 535 nm, respectively.
The percentage of fluorescent intensity at each com-
pound concentration compared with negative control
was indicative of the parasite growth. The dose–re-
sponse curves of fluorescent intensity and compound
concentrations were generated, and IC50, the concentra-
tion of compound to inhibit parasite growth by 50%, was
obtained using SigmaPlot 12.0.
Cytotoxicity test of active uracil-derived compounds
The uracil-derived compounds showing inhibitory ef-
fects on PfUDG were assayed for cytotoxicity to human
Caucasian hepatocyte carcinoma cell line ATCC HB
8665 (HepG2) by in vitro cytotoxicity test [41]. The
methylthiazol tetrazolium (MTT)-dye based colorimetric
microtitration assay was used for detecting cell survival
based on the metabolism of tetrazolium to formazan by
viable cells. The OD of formazan was measured by a
Table 2 Partial purification of native PfUDG
Fraction Volume (ml) Total protein (mg) Total activity (unit) Specific activity Yield (%) Purification fold
Crude extract 18 93.24 1,492.65 16 100 -
Capto™Q (unbound) 6.7 3.64 705.24 193.7 47.25 12.1
HiTrap™ Heparin 0.6 0.024 43.48 1,811.7 2.91 113.2
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vices, CA, USA) at a wavelength of 570 nm. The OD570
represented the cell survival, and the percentage of cell
survival at each compound concentration was deter-
mined by comparing with the OD570 of negative control
lacking compounds. The dose–response curves of % cell
survival, and compound concentrations and IC50 were
obtained. IC50 representing the concentration of com-
pounds providing 50% cell survival indicated the cyto-
toxicity of compounds.
Results
Partial purification of PfUDG from parasite crude extract
The presence of annotated PfUDG in the Plasmodium gen-
ome suggests that P. falciparum would have DNA repair
systems similar to those found in other organisms [21-26].
To address its existence and activity in P. falciparum, theFigure 1 Partial purification of native PfUDG from P. falciparum crude
column with 0-100% KCl linear gradient; B, Capto™Q pooled fraction conta
linear KCl gradient, ■; UDG activity,—; total protein, −–; % KCl.native PfUDG was partially purified from parasite extract
using anion exchange and Heparin Sepharose chromatog-
raphy. The results of the partial purification of PfUDG
are summarized in Table 2. PfUDG activity was found
in unbound fractions for anion exchange column eluted
with 0.1-0.3 M KCl for Heparin Sepharose column
(Figure 1). From 2 ml of parasite pellet, 24 μg of 113
fold-purified PfUDG with a specific activity of 1,811.7
units/mg protein and 2.91% yield were recovered. The
result indicates that PfUDG is functionally active during
the parasite development. Due to the limit enzyme
amount obtained, for further study, the heterologous
expression of PfUDG was persuaded. Nonetheless, some
biochemical properties of this partially purified native
protein were compared to those of the recombinant
PfUDG, to determine if the latter can be used as a rep-
resentative of its native enzyme.extract. A, parasite crude extract was purified on the Capto™Q
ining PfUDG was purified on the HiTrap™ Heparin HP with 0-100%
Figure 2 Analysis of recombinant PfUDG expression by 12%
SDS-PAGE. The gel was stained with Coomassie blue R250. Lane M,
molecular weight markers; lane 1, non-induced whole cells of E. coli
Rosetta expression host; lane 2, 0.5 mM IPTG-induced whole cells of
E. coli Rosetta expression host; lane 3, non-induced whole cell of
E. coli Rosetta carrying PfUDG-constructed vector; lane 4, 0.5 mM
IPTG-induced whole cell of E. coli Rosetta carrying PfUDG-constructed
vector; lane 5, total soluble protein of 0.5 mM IPTG-induced whole cell
of E. coli Rosetta carrying PfUDG-constructed vector; lane 6, Ni-NTA
agarose purified protein. The arrows indicate the completed (40 and
30 kDa) 6-residue histidine-tagged PfUDG.
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The 966-bp full-length PfUDG of P. falciparum strain
K1 was constructed into pET101/D-TOPO expression
vector. The nucleotide sequences showed 99.7% similarity
compared to chloroquine and pyrimethamine-sensitive
P. falciparum 3D7 [NCBI nucleotide reference sequence:
XM_001348285.1] since a single base change (C→A) was
found at the position 469. The base change resulted in
threonine of PfUDG K1 instead of proline of its counter-
part in strain 3D7. In addition, only 24.8% amino acid se-
quence similarity of PfUDG was found compared with the
human enzyme. Moreover, the predicted amino acid se-
quences of PfUDG K1 were much different from UDGs
of other organisms except for Plasmodium vivax as dem-
onstrated in Table 3. The predicted molecular mass of
PfUDG derived from amino acid sequences was about
37.461 kDa [PlasmoDB: PF3D7_1415000].
Expression and purification of recombinant PfUDG
After 1 L scale expresssion, 3.75 g of bacteria were ob-
tained. Approximately 190 mg of total soluble protein were
obtained after disruption, and the recombinant PfUDG was
further purified by Ni-NTA agarose column. After purifica-
tion, two protein bands, ~40 and ~30 kDa, were observed
(Figure 2) with the total amount of 9 mg. The 40-kDa pro-
tein size agrees with the calculated molecular mass for the
sum of 37 kDa PfUDG and 2.4 kDa of 20 amino acids of
C-terminal sequence containing 6 histidine and V5 epitope.
Identification of PfUDG by LC-MS/MS and 3D modelling
of PfUDG
The identities of 40- and 30-kDa proteins were analysed
using tryptic digestion in association with LC-MS/MS.Table 3 Amino acid sequence similarity of PfUDG K1
compared with UDGs from other organisms




P. falciparum 3D7 XP_001348321.1 99.7
P. falciparum IT PF IT_1416000* 99.7
Plasmodium vivax XP_001616803.1 61.2
Homo sapiens (hUNG2) NP_550433.1 24.8
Homo sapiens (hUNG1) NP_003353.1 24.8




Mus musculus isoform A NP_001035781.1 28.6
Mus musculus isoform B NP_035807.2 27.8
T. cruzi CL Brener XP_821835.1 32.1
Herpes simplex virus type 1 NP_044603.1 24.8
Herpes simplex virus type 2 NP_044471.2 24.8
*Gene ID (available in PlasmoDB.org).The peptide fragmentation and mass spectrometric ana-
lysis showed that nine peptide fragments of both pro-
teins were matched to P. falciparum 3D7 UDG sequence
with scores of 278 and 177 respectively (Figure 3A), for
which one of these peptide fragments contained the se-
quence of active site Motif I (water activating motif,
GQDPYH). Therefore, the 40-kDa protein (80% of total
purified protein) was suggested to be a full-length
PfUDG while the 30-kDa protein (20% of total purified
protein) was a truncated/degraded form.
The 3D structure was built from the 214 amino acid se-
quence of PfUDG K1 using human UDG as a template
(Figure 3B). This structure presented 8 α helices and
4 paralled β sheets. The active site motif I (Gly167,
Gln168, Asp169, Pro170, Tyr171, and His172) was located
at a loop connecting β1 strand and α4 and motif II was lo-
cated at the loop linking β4 strand and α8 near the C
terminus of the enzyme. A single amino acid different at
Pro157 for P. falciparum strain 3D7 compared to Thr157
of P. falciparum strain K1 is located at the loop connect-
ing the α3 and β1 strands. Stereochemical quality of the
PfUDG structure generated was validated by PROCHECK
and presented as Ramachandran Plot determined from de-
gree of Phi and Psi angles of each amino acid residue. The
result demonstrated 90.2% amino acid residues in the
most favoured region, 8.2% for additional allowed region,
1.5% for generously allowed region, and 0.0% for disal-
lowed region. Moreover, the root mean square deviation
of PfUDG K1 model was 1.18 compared to the template
analysed by Swiss-PdbViewer Software suggesting the ap-
propriate structure of the PfUDG modelled.
Figure 3 Amino acid sequences and 3D secondary structure of PfUDG. A, Alignments of 9 peptide fragments of PfUDG K1 from LC-MS/MS
to complete amino acid sequences of PfUDG 3D7 and K1. Blue box, the different amino acid between PfUDG 3D7 and K1; yellow box, conserved
amino acid sequences of active site motif I found in fragment 9; B-left, 3D model of PfUDG K1. Cartoon model shows α-helices, blue, β-sheets,
red, coils/loops, green. Thr157 is represented as spheres. N, N terminus and C, C terminus. B-right, Molecular surface represents two motifs of
the enzyme active sites and their residues (bonds and sticks).
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The glycosylase activity of both native and recombinant
PfUDGs was determined using 5' end radiolabelled
41-mer oligonucleotide, for which uracil is present in
the middle of the sequence. Upon the base excision by
UDG and hot alkaline treatment, the 21-mer product
would be generated. Both native and recombinant
PfUDGs possessed UDG activity but lacked of the AP
lyase activity because there was no product generated
without hot alkaline treatment (Figure 4). Therefore,
PfUDG was a monofunctional enzyme.The effects of temperature on PfUDG were examined
from 4 to 65°C. Both native and recombinant PfUDGs
showed highest relative activity at 37°C with 80% and
93%, respectively compared to the initial substrate
(100%) (Figure 5A, 5B). The enzymatic activities de-
creased at either lower or higher temperatures than
37°C. For the pH optimum, the results demonstrated
that the native enzyme functioned in the narrow range
of pH (7–9) compared to that of the recombinant en-
zyme (6–10.5) (Figure 5C, 5D). However, both enzymes
worked well under alkaline conditions. The optimal salt
Figure 4 Enzymatic activity of native and recombinant PfUDGs
with 32P-labelled single stranded oligo-U. Lane 1, the negative
control reaction lacking PfUDGs; lanes 2, 4, and 6, the reactions
without hot alkaline treatment (AP lyase activity assay) were
performed by native , recombinant PfUDG and E. coli UDG
respectively; lanes 3, 5, and 7, the reactions with hot alkaline
treatment (glycosylase activity assay) were performed by native
and recombinant PfUDG and E. coli UDG respectively.
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NaCl with 82% relative activity, whereas enzyme acti-
vity was not observed at lower NaCl concentrations
(Figure 5E, 5F). However, more than 50% inhibition was
found at 100 mM NaCl, and the higher salt concentra-
tions (150–500 mM) showed complete inhibition. High
activity of the recombinant enzyme (87-94%) was ob-
served at 0–100 mM NaCl, while more than 50% en-
zyme inhibition was seen at 150 mM and complete
inhibition occurred at 200–500 mM NaCl. However, the
optimal salt concentrations were 50–75 mM which is in
the same range as found for the native enzyme.
The results indicated that the catalytic reaction of
these enzymes did not require any cofactors. In addition,
both native and recombinant PfUDGs were inhibited by
increasing concentrations of cofactors (Figure 6). For the
substrate preference, both PfUDG enzymes were able to
remove uracil from single stranded oligo-U (ss-U) and
double stranded (ds) A:U, T:U, C:U, and G:U with similar
relative activities (Figure 7).
Based on kinetic parameters of recombinant PfUDG,
there were no significant differences of any kinetic con-
stants using ss-U and ds-A:U as substrates (Table 4).
Compared with the kinetic parameters of human nuclear
uracil N-glycosylase (hUNG2) [27], the substrate affinity
(Km) of PfUDG to ds-A:U was higher than that of
hUNG2, while Km of PfUDG to ss-U was lower than that
of hUNG2. The turnover numbers (kcat) of hUNG2 were
about 2- and 40-fold higher than those of PfUDG both
in ds-A:U and ss-U. The specificity constants (kcat/Km)
of hUNG2 for ds-A:U and ss-U were about 5- and
30-fold higher than those of PfUDG.Inhibitory effects of inhibitors on PfUDG activity, parasite
growth and their cytotoxicity
The inhibitory effect of UGI protein of B. subtilis bacterio-
phage PBS1 on native and recombinant PfUDGs was ana-
lysed using 1:1 molar ratio of PfUDG and UGI. Both native
and recombinant PfUDGs were completely inhibited by
UGI (Figure 8). After testing of 12 uracil-derived com-
pounds against recombinant PfUDG, only two of them,
namely 1-methoxyethyl-6-(p-n-octylanilino)uracil and 6-
(phenylhydrazino)uracil, showed inhibitory effects on
PfUDG activity with IC50s of 16.75 and 77.5 μM, respect-
ively. The rest showed no inhibition even at a concentra-
tion of 400 μM. However, all compounds showed
inhibitory effects on parasite growth with different IC50s.
1-Methoxyethyl-6-(p-n-octylanilino)uracil and 6-(phenyl-
hydrazino)uracil showed IC50s of 15.6 and 12.8 μM,
respectively, whereas the most effective compound against
parasite growth was 6-(p-n-heptylanilino)uracil with IC50 of
5.0 μM. Additionally, 1-methoxyethyl-6-(p-n-octylanilino)
uracil was not toxic to the HepG2 cell line as indicated by
its IC50 value, which is 10 fold greater than that of the para-
site (IC50 of >160 μM vs. 15.6 μM) (Table 5).
Discussion
Usually, UDG works as the key enzyme in the BER path-
way to recognize the uracil base occurring abnormally
during DNA replication [42,43]. Uracil causing G:C to A:
T transition mutations in DNA is harmful to essential
genes of all organisms. Because this enzyme acts in the pri-
mary step to direct further steps of the DNA repair path-
way, inhibition of this enzyme would affect DNA repair of
P. falciparum and eventually may lead to parasite death.
In this study, the existence and activity of PfUDG was
firstly confirmed by isolation and partial purification of
the native PfUDG from parasite extracts using anion ex-
change and Heparin Sepharose chromatography. The
late trophozoites and schizonts were used in this experi-
ment, because they are involved in cell division in which
incorrect DNA replication should occur frequently;
DNA repair is essential for maintenance of genome in-
tegrity during DNA replication to prevent mutation. The
frequency of generated uracil in parasite DNA should be
high during DNA replication similar to other organisms
including human [19,43].
Since the calculated pI value of PfUDG is rather high
(pI 9.78), finding PfUDG in a flow through fraction
when using an anion exchange column with buffer sys-
tem at pH 9 was expected. This step was efficient as
50% UDG activity was recovered, while a large amount
of other proteins was removed (Table 2). After using two
columns, we could not further purify PfUDG to near
homogeneity due to the low amount of enzyme activity,
instability during subsequent purification steps even
in the presence of protease inhibitors, and lack of an
Figure 5 Effects of various temperatures, pH and salt concentrations on native and recombinant PfUDGs. Both native (A, C and E) and
recombinant (B, D and F) PfUDG activities were investigated under various conditions of temperature, pH and NaCl concentration. The negative
control reaction without PfUDG is designated as –ve.
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http://www.malariajournal.com/content/13/1/149affinity column for UDG purification. In addition, culti-
vation of P. falciparum was laborious and much more
medium, human red blood cells and serum would be re-
quired to obtain a higher amount of parasites. Therefore,
heterologous expression of PfUDG was an option pur-
sued in this study.
Escherichia coli is among the most widely used hosts
for heterologous protein production due to its fast
growth rate in cheap media, known genetic property,and ease of use and genetic manipulation. However, ex-
pression of Plasmodium proteins in E. coli can some-
times be challenging [44,45]. Expression of PfUDG in a
general expression BL21 DE3 host yielded PfUDG
mostly as an insoluble protein. However, Rosetta (DE3)
pLysS - a BL21 derivative harbouring extra copies of rare
tRNAs for codons AUA (Ile), AGG (Arg), AGA (Arg),
CUA (Leu), CCC (Pro), and GGA (Gly) significantly im-
proved PfUDG solubility. These rare codons accounted
Figure 6 Effects of divalent cation cofactors on native and recombinant PfUDGs. PfUDG activities of native and recombinant enzymes were
investigated under the assayed condition with the presence of 1, 10, 50 and 100 mM of MgCl2 (A), MnCl2 (B) and CaCl2 (C).
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Figure 7 Effects of substrate types on native and recombinant PfUDGs.Native (A) and recombinant (B) PfUDG activities were investigated
by using different substrates. ss-U, single stranded oligo-U; ds-A:U, double stranded A:U; ds-T:U, double stranded T:U; ds-C:U, double stranded
C:U; ds-G:U, double stranded G:U. The negative control reaction without PfUDG is designated as -ve.
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50% GGA of total codons encoding each amino acid in
PfUDG. With the yield of 9 mg/L culture obtained via the
optimized expression and purification protocols, other
downstream studies such as biochemical characterization
and inhibitor screening could be facilitated. However, a
faint band of incomplete protein was observed during pro-
tein expression as a ~30-kDa protein (Figure 2). This may
be a degraded or truncated form caused by the over-
expression of recombinant protein in the E. coli host,
based on degradation of excess protein by bacterial en-
zymes. Therefore, bacteria may not be the best expression
host for eukaryote PfUDG expression, and the use of a
eukaryote expression host should improve the quality and
yield of protein expression.
It should be mentioned that sequence comparisons
among different P. falciparum strains revealed Thr/
Pro157 polymorphism. Although Proline is present in
other strains, various amino acids including Threonine
are observed in other UDGs, suggesting that this
polymorphism is unlikely to affect enzyme catalysis.Table 4 Kinetic parameters of recombinant PfUDG
Substrate Km (μM) kcat (mi
PfUDG hUNG2* PfUDG
ss-U 1.633 2.2 ± 0.2 59.6
ds-A:U 1.656 0.7 ± 0.1 60.0
Each reaction was performed in 2 independent experiments in a standard reaction
NaCl, 100 μg/ml BSA, 2.5 nM recombinant PfUDG, and 0.01-3.5 μM 32P-labelled sing
*[27].Additionally, this residue is located distantly from the
active site based on the PfUDG modelled structure.
Based on a 3D structure of the recombinant PfUDG,
PfUDG was similar to other organisms as it contains 8
α-helices and 4-paralled β strands [46]. The two active
site motifs are located in positions similar to other
UDGs: motif I located at the loop connecting β1 strand
and α4 helix, and motif II located at the connecting loop
of β4 strand and α8 helix. The stereochemical quality of
the PfUDG structure, which was validated by PRO-
CHECK, confirmed that the modelled structure is suit-
able for study of the molecular interaction between
enzyme and inhibitors.
Biochemical properties such as assay condition, sub-
strate preference, and enzyme inhibition by UGI of
native and recombinant PfUDGs were characterized.
PfUDG is a heat-labile enzyme, and the optimal temperature
of both native and recombinant PfUDG was the same at
37°C. This is the physiological temperature of human
hosts of parasites. This optimal temperature was similar to
that for UDG from other organisms except T. cruzi UDG,n−1) kcat/Km (min
−1/μM−1)
hUNG2* PfUDG hUNG2*
2,768 ± 105 36.50 1,258
137 ± 4 36.23 187
buffer containing 20 mM Tris–HCl, pH 8.0, 1 mM DTT, 1 mM EDTA, 50 mM
le strand oligo-U (ss-U) or double stranded A:U (ds-A:U) at 37°C for 10 min.
Figure 8 Inhibitory effects of UGI of B. subtilis bacteriophage
PBS1 on native and recombinant PfUDGs. Lane 1, the negative
control lacking PfUDG; lanes 2, 4, and 6, the reactions were
performed with native and recombinant PfUDG and E. coli UDG,
respectively; lanes 3, 5, and 7, the reactions were performed with
UGI against native and recombinant PfUDG and E. coli
UDG, respectively.
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forms of PfUDG worked well in alkaline conditions
(pH 7–9), so it is suggested to be one of the pH-
dependent enzymes. This result relates to the optimal pH
of UDG from other organisms [20,24,27].
The optimal NaCl concentrations for both native and
recombinant PfUDGs were 50–75 mM, which are in the
same range of UDG from other organisms, for example
50 mM in hUNG2 [27] and 65 mM in T. cruzi UDG
[24]. The enzyme activity was significantly decreased at
higher NaCl concentrations. The high concentrations of
neutral salts can produce high ionic strength that in-
hibits the activity of many enzymes [47].Table 5 Comparisons of IC50s of uracil-derived compounds in














ND = not-determined.For the cofactor requirement, the native and recom-
binant PfUDGs worked effectively without any divalent
cation cofactors including Mg2+, Mn2+ and Ca2+. Our re-
sults were similar to those for E. coli UDG that did not
require any cofactors for its function [20,21] while UDG
of human [27], vaccinia virus [29] and HSV-2 [48]
showed activity with optimal MgCl2 at 6 mM, 7.5 mM
and 5 mM, respectively. Therefore, PfUDG is suggested
as a cofactor-independent enzyme which is significantly
different from the human enzyme. High concentrations
of divalent cations were suggested to induce structural
changes or interact directly with negatively charged
groups of the enzyme [49]. The native and recombinant
PfUDGs functioned at comparable assay conditions;
however, it was noted that the recombinant enzyme
showed a broader tolerant range of assay conditions.
Based on the results obtained that PfUDG possesses
uracil glycosylase activity for both ss-U and ds-A:U but
lacks AP lyase activity, PfUDG belongs to UDG-family I
[46]. In human, uracil found in double stranded DNA is
generated via cytosine deamination, while that seen in
single stranded DNA is due to misincorporation of the
nucleotide at the replication fork during DNA replica-
tion [27]. Unlike the human enzyme (hUNG2), PfUDG
exhibited similar catalytic efficiency (kcat/Km) toward ss-
U and ds-A:U. The data suggests that PfUDG can serve
to remove uracil resulting from deamination damage
and misincorporation during DNA replication to prevent
gene mutation in the malarial parasite.
Both enzymes were inhibited by UGI protein of bac-
teriophage PBS1 specific to B. subtilis similar to UDG
from other organisms [28-31,50]. Therefore, the recom-
binant enzyme is functionally comparable to the nativetheir inhibitory effects on recombinant PfUDG activity,
IC50 (μM)
PfUDG P. falciparum HepG2 cytotoxicity
16.75 15.6 > 160
77.5 12.8 27.5 ± 4.58
> 400 5.0 ND
> 400 7.1 ND
> 400 7.9 ND
> 400 10.0 ND
> 400 10.0 ND
> 400 10.2 ND
> 400 10.5 ND
> 400 11.0 ND
> 400 12.6 ND
> 400 16.5 ND
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ther studies such as inhibitor screening.
PfUDG was inhibited by two uracil-derived compounds:
1-methoxyethyl-6-(p-n-octylanilino)uracil showed a greater
inhibitory effect (IC50 16.75 μM) than 6-(phenylhydrazino)
uracil (IC50 77.5 μM). Some of the tested compounds were
previously studied for their inhibitory effects on HSV-1
UDG purified from HSV-1-infected HeLa cells and
purified human HeLa UDG and they inhibited HSV-1
UDG more than human UDG based on their IC50s [33].
6-(4-n-Octylanilino)uracil, an analog of 1-methoxyethyl-
6-(p-n-octylanilino)uracil) and 6-(4-n-hexylanilino)uracil
were used to differentiate HSV-1 and human UDG. Based
on our results, four compounds showed no inhibition
of PfUDG (IC50 of > 400 μM), but demonstrated inhibition
of HSV-1 UDG such as 6-(p-n-butylanilino)uracil (IC50
of 150 μM), 6-(p-n-pentylanilino)uracil (IC50 of 30 μM),
6-(p-i-pentylanilino)uracil (IC50 of 140 μM), and 6-(p-n-
heptylanilino)uracil (IC50 of 20 μM) [33]. Therefore, these
four compounds can be used to differentiate HSV-1 UDG
and PfUDG. This result confirmed that there are some dif-
ferences between the malarial enzyme (PfUDG) and viral
enzyme (HSV-1 UDG). Moreover, 1-methoxyethyl-6-(p-n-
octylanilino)uracil exhibited significant inhibitory effects
on PfUDG (IC50 of 16.75 μM) while 6-(4-n-octylanilino)
uracil showed no inhibitory effects on human UDG (IC50
of > 300 μM) [33]. The 1-methoxyethyl-6-(p-n-octylani-
lino)uracil and other series of alkylanilinouracils should be
further tested for their inhibitory effects on human UDG.
Among 12 inhibitors, 1-methoxyethyl-6-(p-n-octylanilino)
uracil exhibited the most potent anti-PfUDG activity with
anti-malarial activity. Additionally, this compound was not
cytotoxic to HepG2 cells (IC50 was 10 folds greater than
that of P. falciparum). The data here indicate the dissimi-
lar binding sites between the parasite and human
enzymes, hence rational design for a selective inhibitor
against PfUDG can be achieved. Furthermore, 1-
methoxyethyl-6-(p-n-octylanilino)uracil can serve as a
starting template for development of new antiplasmo-
dial agents. Molecular docking of this analog and
PfUDG in comparison to that of human enzyme is being
explored to reveal the distinct binding modes and mo-
lecular interactions between these enzymes and inhibi-
tor to aid the rational drug design.
Conclusions
The native and recombinant PfUDGs were characterized
for biochemical properties. Results demonstrated that
there is no significant difference between them. There-
fore, recombinant PfUDG can be used to screen for
active compounds targeting this parasite enzyme. The re-
combinant enzyme was inhibited by two uracil-derived
compounds, 1-methoxyethyl-6-(p-n-octylanilino)uracil and
6-(phenylhydrazino)uracil, and these compounds inhibitedparasite growth. The first compound was not toxic to
HepG2 cell lines while the latter one was cytotoxic.
These results indicate that PfUDG may act as a good
target against malaria, and newly synthesized uracil-
derived compounds should be further developed to have
the most effective and least toxic anti-malarial drug in
the future.
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